E
Entegrion
Life sciences company dedicated to providing innovative solutions
About Entegrion
Entegrion is a privately held life sciences company dedicated to providing innovative solutions for clinical diagnosis and management of hemostasis, which is the process that stops bleeding. The company focuses on developing advanced diagnostic tools and treatment solutions that help clinicians improve patient outcomes. Entegrion's flagship product, the VCM™ system, offers rapid assessment of hemostasis in a portable, chemistry-free system designed for near-patient use. This product is particularly useful for clinicians who need quick and accurate diagnostic information to manage patients with compromised hemostatic states.
Entegrion operates primarily in the healthcare market, serving clinicians and medical institutions that require advanced diagnostic and treatment solutions. The company collaborates with leading scientists, clinicians, and industry specialists to bring its products from research and development to market. One of its significant partners is the U.S. Department of Defense, which has awarded Entegrion over $100 million in product development contracts.
The business model of Entegrion involves the development, manufacturing, and commercialization of its diagnostic and treatment solutions. Revenue is generated through the sale of these products to medical institutions and through partnerships with other companies in the healthcare sector.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2002
- Headquarters
- United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 41.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Military, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jul 2022 | $20M | $80M | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | Jul 2022 | $14M | $55M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Entegrion is 590 monthly website visits, up 227.8% over the last three months. Entegrion's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Entegrion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Entegrion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.